These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8827212)

  • 1. The role of HIV type 1 phenotype and genotype in long-term responders to zidovudine therapy.
    Angarano G; Monno L; Vivirito MC; Appice A; Romanelli C; Giannelli A; La Grasta L; Fracasso C; Fiore JR; Milazzo F
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):969-75. PubMed ID: 8827212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
    Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
    Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
    Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
    AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
    van't Wout AB; Ran LJ; de Jong MD; Bakker M; van Leeuwen R; Notermans DW; Loeliger AE; de Wolf F; Danner SA; Reiss P; Boucher CA; Lange JM; Schuitemaker H
    J Clin Invest; 1997 Nov; 100(9):2325-32. PubMed ID: 9410911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals.
    Bratt G; Leandersson AC; Albert J; Sandström E; Wahren B
    AIDS; 1998 May; 12(7):729-36. PubMed ID: 9619804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syncytium-inducing phenotype and zidovudine susceptibility of HIV-1 isolated from post-mortem tissue.
    McGavin CH; Land SA; Sebire KL; Hooker DJ; Gurusinghe AD; Birch CJ
    AIDS; 1996 Jan; 10(1):47-53. PubMed ID: 8924251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
    Boucher CA; Lange JM; Miedema FF; Weverling GJ; Koot M; Mulder JW; Goudsmit J; Kellam P; Larder BA; Tersmette M
    AIDS; 1992 Nov; 6(11):1259-64. PubMed ID: 1282015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential determination of viral load and phenotype in human immunodeficiency virus type 1 infection.
    Daar ES; Chernyavskiy T; Zhao JQ; Krogstad P; Chen IS; Zack JA
    AIDS Res Hum Retroviruses; 1995 Jan; 11(1):3-9. PubMed ID: 7734193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children.
    Tuttle DL; Anders CB; Aquino-De Jesus MJ; Poole PP; Lamers SL; Briggs DR; Pomeroy SM; Alexander L; Peden KW; Andiman WA; Sleasman JW; Goodenow MM
    AIDS Res Hum Retroviruses; 2002 Mar; 18(5):353-62. PubMed ID: 11897037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization.
    De Wolf F; Hogervorst E; Goudsmit J; Fenyö EM; Rübsamen-Waigmann H; Holmes H; Galvao-Castro B; Karita E; Wasi C; Sempala SD
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1387-400. PubMed ID: 7888192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Frequency and characteristics of patients treated with zidovudine and absence of progression of HIV infection].
    Soriano V; Heredia A; Mas A; Vallejo A; Garćia-Lerma G; Bravo R; Gómez-Cano M; Villalba N; Moreno V; Laguna F; Valencia E; Martínez P; González-Lahoz J
    An Med Interna; 1997 Jun; 14(6):282-5. PubMed ID: 9410098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-syncytium-inducing HIV type 1 isolated from infected individuals replicates in MT-2 cells.
    Forte SE; Byron KS; Sullivan JL; Somasundaran M
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1613-8. PubMed ID: 7888220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.
    Rusconi S; De Pasquale MP; Milazzo L; Moscatelli G; Bulgheroni E; Citterio P; d'Arminio-Monforte A; Moroni M; Galli M
    Antivir Ther; 1997 Jan; 2(1):39-46. PubMed ID: 11322265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term intake of Korean red ginseng in HIV-1-infected patients: development of resistance mutation to zidovudine is delayed.
    Cho YK; Sung H; Lee HJ; Joo CH; Cho GJ
    Int Immunopharmacol; 2001 Jul; 1(7):1295-1305. PubMed ID: 11460310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 viraemia changes in patients with and without syncytium-inducing phenotype treated with nucleoside analogues: a case-control study.
    Leal M; Torres Y; Medrano FJ; Rey C; Caruz A; Sánchez-Quijano A; Lissen E
    Eur J Clin Invest; 1996 Oct; 26(10):923-8. PubMed ID: 8911867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity.
    Ercoli L; Sarmati L; Nicastri E; Giannini G; Galluzzo C; Vella S; Andreoni M
    AIDS; 1997 Aug; 11(10):1211-7. PubMed ID: 9256938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional mutations detected in sequential HIV-1 isolates from ZDV-treated patients.
    Magierowska-Jung M; Agut H; Katlama C; Autran B; Huraux JM
    J Med Virol; 1997 Jan; 51(1):48-55. PubMed ID: 8986949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B; Pellegrin I; Ruffault A; Ragnaud JM; Morlat P; Michelet C; Doignon F; Biteau N; Fleury HJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):330-4. PubMed ID: 7533640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.